This document is a publication of a European patent application (EP4301776A1) for a periostin antibody intended for therapeutic use in treating inflammation, fibrosis, and lung diseases. The patent was published by the European Patent Office (EPO) on March 11, 2026, with the Centre National de la Recherche Scientifique (CNRS) and Université d'Orléans listed as applicants.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future developments in therapeutic treatments for the specified conditions. Companies in the pharmaceutical and biotechnology sectors may wish to monitor the progress of this patent application and related research for competitive intelligence and potential licensing or collaboration opportunities.